학술논문

CCNE1 and survival of patients with tubo‐ovarian high‐grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study
Document Type
article
Author
Kang, Eun‐YoungWeir, AshleyMeagher, Nicola SFarrington, KyoNelson, Gregg SGhatage, PrafullLee, Cheng‐HanRiggan, Marjorie JBolithon, AdelynPopovic, GordanaLeung, BettyTang, KatrinaLambie, NeilMillstein, JoshuaAlsop, JenniferAnglesio, Michael SAtaseven, BeyhanBarlow, EllenBeckmann, Matthias WBerger, JessicaBisinotto, ChristianiBösmüller, HansBoros, JessicaBrand, Alison HBrooks‐Wilson, AngelaBrucker, Sara YCarney, Michael ECasablanca, YovanniCazorla‐Jiménez, AliciaCohen, Paul AConrads, Thomas PCook, Linda SCoulson, PennyCourtney‐Brooks, MadeleineCramer, Daniel WCrowe, PhilipCunningham, Julie MCybulski, CezaryDarcy, Kathleen MEl‐Bahrawy, Mona AElishaev, EstherErber, RamonaFarrell, RhondaFereday, SianFischer, AnnaGarcía, María JGayther, Simon AGentry‐Maharaj, AleksandraGilks, C BlakeGroup, AOCSGrube, MarcelHarnett, Paul RHarrington, Shariska PetersenHarter, PhilippHartmann, ArndtHecht, Jonathan LHeikaus, SebastianHein, AlexanderHeitz, FlorianHendley, JoyHernandez, Brenda YPolo, Susanna HernandoHeublein, SabineHirasawa, AkiraHøgdall, EstridHøgdall, Claus KHorlings, Hugo MHuntsman, David GHuzarski, TomaszJewell, AndreaJimenez‐Linan, MercedesJones, Michael EKaufmann, Scott HKennedy, Catherine JKhabele, DineoKommoss, Felix KFKruitwagen, Roy FPMLambrechts, DietherLe, Nhu DLener, MarcinLester, JennyLeung, YeeLinder, AnnaLoverix, LiseloreLubiński, JanMadan, RashnaMaxwell, G LarryModugno, FrancesmaryNeuhausen, Susan LOlawaiye, AlexanderOlbrecht, SielOrsulic, SandraPalacios, JoséPearce, Celeste LeighPike, Malcolm CQuinn, Carmel MMohan, Ganendra RajRodríguez‐Antona, CristinaRuebner, MatthiasRyan, Andy
Source
Cancer. 129(5)
Subject
Biomedical and Clinical Sciences
Oncology and Carcinogenesis
Cancer
Clinical Research
Ovarian Cancer
Rare Diseases
2.1 Biological and endogenous factors
Aetiology
Female
Humans
Ovarian Neoplasms
Transcription Factors
Carcinoma
RNA
Messenger
Cystadenocarcinoma
Serous
Oncogene Proteins
Cyclin E
CCNE1 amplification
cyclin E1 expression
high-grade serous carcinoma
ovarian cancer
prognosis
AOCS Group
Public Health and Health Services
Oncology & Carcinogenesis
Oncology and carcinogenesis
Public health
Language
Abstract
BackgroundCyclin E1 (CCNE1) is a potential predictive marker and therapeutic target in tubo-ovarian high-grade serous carcinoma (HGSC). Smaller studies have revealed unfavorable associations for CCNE1 amplification and CCNE1 overexpression with survival, but to date no large-scale, histotype-specific validation has been performed. The hypothesis was that high-level amplification of CCNE1 and CCNE1 overexpression, as well as a combination of the two, are linked to shorter overall survival in HGSC.MethodsWithin the Ovarian Tumor Tissue Analysis consortium, amplification status and protein level in 3029 HGSC cases and mRNA expression in 2419 samples were investigated.ResultsHigh-level amplification (>8 copies by chromogenic in situ hybridization) was found in 8.6% of HGSC and overexpression (>60% with at least 5% demonstrating strong intensity by immunohistochemistry) was found in 22.4%. CCNE1 high-level amplification and overexpression both were linked to shorter overall survival in multivariate survival analysis adjusted for age and stage, with hazard stratification by study (hazard ratio [HR], 1.26; 95% CI, 1.08-1.47, p = .034, and HR, 1.18; 95% CI, 1.05-1.32, p = .015, respectively). This was also true for cases with combined high-level amplification/overexpression (HR, 1.26; 95% CI, 1.09-1.47, p = .033). CCNE1 mRNA expression was not associated with overall survival (HR, 1.00 per 1-SD increase; 95% CI, 0.94-1.06; p = .58). CCNE1 high-level amplification is mutually exclusive with the presence of germline BRCA1/2 pathogenic variants and shows an inverse association to RB1 loss.ConclusionThis study provides large-scale validation that CCNE1 high-level amplification is associated with shorter survival, supporting its utility as a prognostic biomarker in HGSC.